1. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer
   Shirish M Gadgeel, 2018, Future Oncology CrossRef
2. Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma
   John A. Heath et al, 2018, Pediatr Blood Cancer CrossRef
3. Rack1 mediates Src binding to drug transporter P-glycoprotein and modulates its activity through regulating Caveolin-1 phosphorylation in breast cancer cells
   Yanling Fan et al, 2019, Cell Death Dis CrossRef
4. Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine
   Guangyan Du et al, 2020, J. Med. Chem. CrossRef
5. Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest
   Takuma Yamashita et al, 2020, Anti-Cancer Drugs CrossRef
6. Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
   Olaf Beck et al, 2020, Cancers CrossRef
7. ALK Inhibitors-Induced M Phase Delay Contributes to the Suppression of Cell Proliferation
   Sirajam Munira et al, 2020, Cancers CrossRef
8. Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer
   Elisabeth Smolle et al, 2021, Cancers CrossRef
9. EML4-ALK induces cellular senescence in mortal normal human cells and promotes anchorage-independent growth in hTERT-transduced normal human cells
   Akihiko Miyanaga et al, 2021, BMC Cancer CrossRef
10. Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition
    Marcel Kemper et al, 2021, Oncotarget CrossRef
11. GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer
    Yuki Shimizu et al, 2022, npj Precis. Onc. CrossRef
12. ALK-Positive Non-Small Cell Lung Cancer; Potential Combination Drug Treatments
    Shrestha Nensi et al, 2021, CCDT CrossRef
13. Lorlatinib as a treatment for ALK-positive lung cancer
    Keisuke Baba et al, 2022, Future Oncology CrossRef
14. Experimental Determination of Cancer Drug Targets with Independent Mechanisms of Resistance
    Abigail R. Bland et al, 2022, CCDT CrossRef
15. Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism
    Bo Xie et al, 2022, Clin Transl Oncol CrossRef
16. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
    Yang Yang et al, 2022, Sig Transduct Target Ther CrossRef
17. Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
    Yuki Katayama et al, 2023, npj Precis. Onc. CrossRef
18. EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveries
    Mariam Elshatlawy et al, 2023, Molecular Oncology CrossRef
19. Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L)
    Yuichi Ozawa et al, 2024, Ther Adv Med Oncol CrossRef
20. Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions
    Hannaneh Parvaresh et al, 2024, Biomedicines CrossRef
21. Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome
    Alberto Diaz-Jimenez et al, 2024, Drug Resistance Updates CrossRef
22. AXL and SHC1 confer crizotinib resistance in patient-derived xenograft model of ALK-driven lung cancer
    Yerong Hu et al, 2024, iScience CrossRef